Mechanisms and measurement of dyspnea in chronic obstructive pulmonary disease

Proceedings of the American Thoracic Society

Volumn 3, Issue 3, 2006, Pages 234-238

  Mahler, Donald A ^a,b  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

Author keywords

Clinical dyspnea instruments; Descriptors of breathlessness; Exercise testing; Neuroventilatory dissociation

Indexed keywords

CENTRAL NERVOUS SYSTEM; CHEMORECEPTOR; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL FEATURE; COMPUTER PROGRAM; CONFERENCE PAPER; DAILY LIFE ACTIVITY; DISEASE SEVERITY; DYSPNEA; EXERCISE; HUMAN; MECHANORECEPTOR; MEDICAL INFORMATION; MEDICAL INSTRUMENTATION; MEDICAL PRACTICE; NEUROPHYSIOLOGY; OUTCOME ASSESSMENT; PHYSICAL ACTIVITY; PHYSICAL CAPACITY; PSYCHOPHYSICS;

DYSPNEA; EXERCISE TEST; HEALTH STATUS INDICATORS; HUMANS; MODELS, BIOLOGICAL; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 33646340678     PISSN: 15463222     EISSN: 15463222     Source Type: Journal    
DOI: 10.1513/pats.200509-103SF     Document Type: Conference Paper

References (58)

1. Rennard S, Decramer M, Calverly PMA, Pride NB, Soriano JB, Vermeire PA, Vestbo J. Impact of COPD in North America and Europe in 2000: subjects' perspective of confronting COPD. International Survey. Eur Respir J 2002;20:799-805.
2. American Thoracic Society. Dyspnea: mechanisms, assessment, and management: a consensus statement. Am J Respir Crit Care Med 1999;159:321-340.
3. Mahler DA, Harver A, Lentine T, Scott JA, Beck K, Schwartzstein RM. Descriptors of breathlessness in cardiorespiratory diseases. Am J Respir Crit Care Med 1996;154:1357-1363.
4. O'Donnell DE, Bertley JC, Chau LK, Webb KA. Qualitative aspects of exertional breathlessness in chronic airflow limitation: pathophysiologic mechanisms. Am J Respir Crit Care Med 1997;155:109-115.
5. Manning HL, Schwartzstein RM. Pathophysiology of dyspnea. N Engl J Med 1995;333:1547-1553.
6. Schwartzstein RM, Lahive K, Pope A, Weinberger SE, Weiss JW. Cold facial stimulation reduces breathlessness induced in normal subjects. Am Rev Respir Dis 1987;136:58-61.
7. O'Donnell DE, Sanii R, Anthonisen NR, Younes M. Effect of dynamic airway compression on breathing pattern and respiratory sensation in severe chronic obstructive pulmonary disease. Am Rev Respir Dis 1987;135:912-918.
8. O'Donnell DE, Webb KA. Exertional breathlessness in patietns with chronic airflow limitation: the role of lung hyperinflation. Am Rev Respir Dis 1993;148:1351-1357.
9. O'Donnell DE, Fluge T, Gerken F, Hamilton A, Webb K, Aguilaniu B, Make B, Magnussen H. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J 2004;23:832-840.
10. Calverly P, Pauwels R, Vestbo J, Jones P, Pride N, Gulsvik A, Anderson J, Maden C. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003;361:449-456.
11. Mahler DA, Wire P, Horstman D, Chang CN, Yates J, Fischer T, Shah T. Effectiveness of fluticasone propionate and salmeterol combination delivered via the diskus device in the treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002;166:1084-1091.
12. Mahler DA, Huang S, Tabrizi M, Bell GM. Efficacy and safety of a monoclonal antibody recognizing interleukin-8 in COPD: a pilot study. Chest 2004;126:926-934.
13. Killian KJ, Gandevia SC, Summer E, Campbell EJM. Effect of increased lung volume on perception of breathlessness. J Appl Physiol 1984;57:686-691.
14. O'Donnell DE, Webb KA. Exertional breathlessness in patients with chronic airflow limitation. Am Rev Respir Dis 1993;148:1351-1357.
15. Banzett RB, Lansing RW, Brown R. "Air hunger" from increased PCO2 persists after complete neuromuscular block in humans. Respir Physiol 1990;81:1-17.
16. Noseda A, Schmerber J, Prigogine T, Yernault JC. Perceived effect on shortness of breath of an acute inhalation of saline or terbutaline: variability and sensitivity of a visual analogue scale in patients with asthma or COPD. Eur Respir J 1992;5:1043-1053.
17. Mahler DA, Rosiello RA, Harver A, Lentine T, McGovern JF, Daubenspeck JA. Comparison of clinical dyspnea ratings and psychophysical measurements of respiratory sensation in obstructive airway disease. Am Rev Respir Dis 1987;135:1229-1233.
18. Hamilton AL, Killian KJ, Summers E, Jones NL. Symptom intensity and subjective limitation to exercise in patients with cardiorespiratory disorders. Chest 1996;110:1255-1263.
19. Fierro-Carrion G, Mahler DA, Ward J, Baird JC. Comparison of continuous and discrete measurements of dyspnea during exercise in patients with COPD and normal subjects. Chest 2004;125:77-84.
20. Lavietes MH, Sanchez CW, Tiersky LA, Cherniack NS, Natelson BH. Psychological profile and ventilatory response to inspiratory resistive loading. Am J Respir Crit Care Med 2000;161:737-744.
21. Carrieri-Kohlman V, Gormley JM, Douglas MK, Paul SM, Stulbarg MS. Differentiation between dyspnea and its affective components. West J Nurs Res 1996;18:626-642.
22. Baird JC, Noma E. Fundamentals of scaling and psychophysics. New York: Wiley Interscience; 1978.
23. Fletcher CM. The clinical diagnosis of pulmonary emphysema - an experimental study. Proc R Soc Med 1952;45:577-584.
24. Fletcher CM, Elmes PC, Wood CH. The significance of respiratory symptoms and the diagnosis of chronic bronchitis in a working population. BMJ 1959;2:257-266.
25. Aitken RCB. Measurement of feelings using visual analogue scales. Proc R Soc Med 1969;62:989-993.
26. McGavin CR, Artvinli M, Naoe H. Dyspnea, disability, and distance walked: comparison of estimates of exercise performance in respiratory disease. BMJ 1978;2:241-243.
27. Rose GA, Blackburn H, Gillum RF. Cardiovascular survey methods, 2nd ed. Geneva: World Health Organization; 1982. p. 166. WHO Monograph Series, No. 56, Annex 7.
28. Brooks SM. Task force on surveillance for respiratory hazards in the occupational setting. Surveillance for respiratory hazards. ATS News 1982;8:12-16.
29. Leidy NK, Rennard SI, Schmier J, Jones KC, Goldman M. The breathlessness, cough, and sputum scale. Chest 2003;124:2182-2191.
30. Mahler DA, Weinberg DH, Wells CK, Feinstein AR. The measurement of dyspnea: contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest 1984;85:751-758.
31. Guyatt GH, Berman LB, Townsend M, Pugsley SO, Chambers LW. A measure of quality of life for clinical trials in chronic lung disease. Thorax 1987;42:773-778.
32. Eakin EG, Resnikoff PM, Prewitt LM, Ries AL, Kaplan RM. Validation of a new dyspnea measure: the UCSD shortness of breath questionnaire. Chest 1998;113:619-624.
33. Mahler DA, Ward J, Fierro-Carrion G, Waterman LA, Lentine TF, Mejia-Alfaro R, Baird JC. Development of self-administered versions of modified Baseline and Transition Dyspnea Indexes in COPD. J COPD 2004;1:165-172.
34. Mahler DA, Waterman LA, Ward J, Lentine TF, Tomlinson D, Baird JC. Validity and responsiveness of the self-administered computerized (SAC) versions of the Baseline (BDI) and Transition (TDI) Dyspnea Indexes in COPD [abstract]. Proc Am Thoracic Soc 2005;2:A643.
35. Williams JE, Singh SJ, Sewell L, Morgan MD. Health status measurement: sensitivity of the self-reported chronic respiratory questioinnaire (CRQ-SR) in pulmonary rehabilitation. Thorax 2003;58:515-518.
36. Schunemann HJ, Goldstein R, Mador MJ, McKim D, Stahl E, Puhan M, Griffith LE, Grant B, Austin P, Collins R, et al. A randomised trial to evaluate the self-administered standardised chronic respiratory questionnaire. Eur Respir J 2005;25:31-40.
37. Nishimura K, Izumi T, Tsukino M, Oga T. Dyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPD. Chest 2002;121:1434-1440.
38. Celli BR, Cote CG, Marin JM, Casanova C, Montes de Oca M, Mendez RA, Pinto Plata V, Cabral HJ. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 2004;350:1005-1012.
39. Mahler DA. Measurement of dyspnea: clinical ratings. In: Mahler DA, O'Donnell DE, eds. Dyspnea: mechanisms, measurement, and management. New York: Taylor & Francis Books, Inc.; 2005. pp. 147-164.
40. O'Donnell DE, McGuire MA, Samis L, Webb KA. The impact of exercise reconditioning on breathlessness in severe chronic airflow limitation. Am J Respir Crit Care Med 1995;152:2005-2013.
41. Vincken W, van Noord JA, Greefhorst APM, Bantje TA, Kesten S, Korducki L, Cornelissen PJG. Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur Respir J 2002;19:209-216.
42. Casaburi R, Mahler DA, Jones PW, Wanner A, San Pedro G, ZuWallack RL, Menjoge SS, Serby CW, Witek T Jr. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002;19:217-224.
43. Ries AL, Kaplan RM, Limberg TM, Prewitt LM. Effects of pulmonary rehabiliatation on physiologic and psychosocial outcomes in patients with chronic obstructive pulmonary disease. Ann Intern Med 1995;122:823-832.
44. Readon J, Awad E, Normandin E, Vale F, Clark B, ZuWallack RL. The effect of comprehensive outpatient pulmonary rehabilitation on dyspnea. Chest 1994;105:1046-1052.
45. Martinez FJ, Montes de Oca M, Whyte RI, Stetz J, Gay SE, Celli BR. Lung-volume reduction improves dyspnea, dynamic hyperinflation, and respiratory muscle function. Am J Respir Crit Care Med 1997;155:1984-1990.
46. Lisboa C, Munoz V, Beroiza T, Leiva A, Cruz E. Inspiratory muscle training in chronic airflow limitation: comparison of two different training loads with a threshold device. Eur Respir J 1994;7:1266-1274.
47. Witek TJ Jr, Mahler DA. Meaningful effect size and patterns of response of the transiiton dyspnea index. J Clin Epidemiol 2003;56:248-255.
48. Witek TJ Jr, Mahler DA. Minimal important difference of the transition dyspnoea index in a multinational clinical trial. Eur Respir J 2003;21:1-6.
49. Schunemann HJ, Puhan M, Goldstein R, Jaeschke R, Guyatt GH. Measurement properties and interpretability of the Chronic Respiratory Disease Questionnaire. J COPD 2005;2:81-89.
50. Mahler DA, Fierro-Carrion G, Baird JC. Mechanisms and measurement of exertional dyspnea. In: Weisman IM, Zeballos RJ, editors. Clinical exercise testing. Progress in Respiratory Research, vol. 32. Basel: Karger; 2002;32:72-80.
51. Borg GAV. Psychological bases of perceived exertion. Med Sci Sports Exerc 1982;14:377-381.
52. Gift AG. Visual analogue scales: measurement of subjective phenomena. Nurs Res 1989;38:286-288.
53. Mejia R, Ward J, Lentine T, Mahler DA. Target dyspnea ratings predict expected oxygen consumption as well as target heart rate values. Am J Respir Crit Care Med 1999;159:1485-1489.
54. Killian KJ, LeBlanc P, Martin DH, Summers E, Jones NL, Campbell EJM. Exercise capacity and ventilatory, circulatory, and symptom limitation in patients with chronic airflow limitation. Am Rev Respir Dis 1992;146:935-940.
55. Man WD, Soliman MG, Gearing J, Radford SG, Rafferty GF, Gray BJ, Polkey MI, Moxham J. Symptoms and quadriceps fatigability after walking and cycling in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003;168:562-567.
56. Harty HR, Heywood P, Adams L. Comparison between continuous and discrete measurements of breathlessness during exercise in normal subjects using a visual anlogue scale. Clin Sci 1993;85:229-236.
57. Mahler DA, Mejia-Alfaro R, Ward J, Baird JC. Continuous measurement of breathlessness during exercise: validity, reliability, and responsiveness. J Appl Physiol 2001;90:2188-2196.
58. Mahler DA, Fierro-Carrion G, Mejia-Alfaro R, Ward J, Baird JC. Responsiveness of continuous ratings of dyspnea during exercise in patients with COPD. Med Sci Sports Exerc 2005;37:529-535.